HYPD:NASDAQHyperion DeFi, Inc. Analysis
Data as of 2026-04-09 - not real-time
$3.21
Latest Price
8/10Risk
Risk Level: High
Executive Summary
The stock is trading well below its 200‑day moving average while the 20‑day average sits just under the 50‑day average, signaling a bearish long‑term trend but a relatively tight short‑term positioning. The relative strength index hovers near the midpoint, indicating the price is not in an extreme overbought or oversold condition. A negative MACD histogram and a bearish crossover further reinforce downward momentum on the chart. Recent volume has been tapering and the 30‑day price volatility is exceptionally high, suggesting that price swings may be amplified. The company’s beta is markedly above one, meaning it tends to move more aggressively than the broader market.
On the fundamentals side, revenue growth has accelerated and gross margins remain healthy, demonstrating strong top‑line momentum. However, operating losses, negative cash flow and a debt load that dwarfs equity raise concerns about sustainability. The price‑to‑book ratio is well under one, implying that the market valuation is modest relative to the balance sheet, whereas the price‑to‑sales multiple is elevated. Analysts have issued a strong‑buy consensus and set a target price that is nearly double the current level, reflecting optimism from recent partnership announcements. The firm’s latest partnership with a trading platform and its expanding DeFi business lines are expected to drive a multi‑fold increase in adjusted gross profit this year. Despite the upside potential, the combination of high volatility, leverage and regulatory exposure makes the stock a high‑risk play. Investors should weigh the bullish growth narrative against the fragile financial footing and market‑technical headwinds before deciding.
On the fundamentals side, revenue growth has accelerated and gross margins remain healthy, demonstrating strong top‑line momentum. However, operating losses, negative cash flow and a debt load that dwarfs equity raise concerns about sustainability. The price‑to‑book ratio is well under one, implying that the market valuation is modest relative to the balance sheet, whereas the price‑to‑sales multiple is elevated. Analysts have issued a strong‑buy consensus and set a target price that is nearly double the current level, reflecting optimism from recent partnership announcements. The firm’s latest partnership with a trading platform and its expanding DeFi business lines are expected to drive a multi‑fold increase in adjusted gross profit this year. Despite the upside potential, the combination of high volatility, leverage and regulatory exposure makes the stock a high‑risk play. Investors should weigh the bullish growth narrative against the fragile financial footing and market‑technical headwinds before deciding.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish technical indicators and decreasing volume
- High price volatility and elevated beta
- Recent revenue acceleration and partnership news
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Projected multi‑fold increase in adjusted gross profit
- Strong analyst target price and consensus
- Low price‑to‑book suggesting balance‑sheet upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Expanding DeFi ecosystem and strategic partnerships
- Potential to capture market share in ophthalmic technology
- Long‑term upside to target price despite current financial headwinds
Key Metrics & Analysis
Financial Health
Revenue Growth1666.40%
ROE-324.08%
ROA-41.89%
Debt/Equity20.74
P/B Ratio0.7
Op. Cash Flow$-14770174
Free Cash Flow$-9045627
Industry P/E26.4
Technical Analysis
TrendBearish
RSI46.1
Support$2.92
Resistance$4.03
MA 20$3.44
MA 50$3.48
MA 200$6.20
MACDBearish
VolumeDecreasing
Fear & Greed Index83.45
Valuation
Target Price$6.28
Upside/Downside95.48%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.69
Volatility98.55%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.